| Nov 4 |
Nuwellis Receives Increased Reimbursement Rate for Aquadex SmartFlow® Therapy from the Centers for Medicare and Medicaid
|
| Nov 1 |
Nuwellis shares nearly doubled on higher than expected Q3 prelim revenue
|
| Nov 1 |
Nuwellis Announces Preliminary Results for Third Quarter of 2024
|
| Oct 31 |
Nuwellis Welcomes University of Iowa Health Care Stead Family Children’s Hospital as Newest Pediatric Customer
|
| Oct 23 |
Nuwellis, Inc. To Report Third Quarter 2024 Financial Results on November 11, 2024
|
| Sep 25 |
Nuwellis to Present at the Third Annual ROTH Healthcare Opportunities Conference
|
| Aug 27 |
New Study Published in Current Problems in Cardiology Highlights Statistically Significant Reduction in Heart Failure Readmissions at 60 days when using the Aquadex Ultrafiltration Therapy
|
| Aug 23 |
Nuwellis to sell 496,901 shares at $1.845 in registered direct offering
|
| Aug 23 |
Nuwellis Announces Pricing of $916,000 Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
|
| Aug 13 |
Nuwellis, Inc. (NUWE) Q2 2024 Earnings Call Transcript
|
